linjc16/ctgov huggingface dataset:
Clinical and Electrophysiological Patterns of Chronic Dysimmune Polyneuropathy

Study Overview
=================
Brief Summary
-----------------
Chronic dysimmune neuropathies (CDN) are a heterogenous group of acquired inflammatory demyelinating neuropathies including chronic inflammatory demyelinating polyneuropathies (CIDP), Lewis-Sumner Syndrome (LSS), multifocal motor neuropathy (MMN) and other rare entities. Despite their relatively low prevalence, CDN lead to substantial costs for patients and society. CDN are usually misdiagnosed due to progressive nature of the disease with little known data regarding disease activity and treatment response

Detailed Description
-----------------
CIDP is the most common treatable CDN worldwide. Its prevalence is ranging between approximately 1 to 8.9 cases per 100.000 . In addition, there is often the tendency to diagnose CIDP in order to attempt a treatment option. This ultimately leads to overdiagnosis and overtreatment in some patients Although the different CDN have varying underlying pathophysiology and clinical characteristics, they are all potentially treatable with immunomodulatory drugs. To date, diagnostic criteria, measurement of disease activity and treatment response of CDN are mainly based on clinical, electrophysiological, and patient related outcome parameters. The commonly used EFNS/PNS diagnostic criteria for CIDP seems to have the best sensitivity among different sets of diagnostic criteria

Official Title
-----------------
Clinical and Electrophysiological Patterns of Chronic Dysimmune Polyneuropathy Among Patients Attending Neuropsychiatry Department - Assiut University

Conditions
-----------------
Chronic Inflammatory Demyelinating Polyneuropathy

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age > 18 years, both sexes, history of sensory and/or motor complaint with progressive course over more 2 months Exclusion Criteria: *Patients with systemic diseases (DM, chronic kidney or liver disease, thyroid disease, vitamin B12 deficiency) Family history of peripheral neuropathy or neurological symptoms suggestive for heredo-familial neurological disorders Patients with infective cause as (HBV, HCV, HIV, leprosy) Toxic and drug induced polyneuropathy (chemotherapeutics, antimicrobial ..

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of patients diagnosed with chronic inflammatory demyleinating polyneuropathy attending neuropsychiatry department Assiut university | Number of patients diagnosed with chronic inflammatory demyleinating polyneuropathy attending neuropsychiatry department Assiut university | From January 2023 to December 2026 |
Lower Urinary Tract Dysfunction Database

Study Overview
=================
Brief Summary
-----------------
Patients with neurological disease/injury often suffer from lower urinary tract symptoms, which frequently have a negative impact on the patients' health related quality of life. The prevalence of lower urinary tract dysfunction is high and the treatment is a challenge because available treatments may fail. In this study data of patients with lower urinary tract dysfunction treated at the University of Zürich, are prospectively and systematically collected in a database.

Detailed Description
-----------------
Lower urinary tract dysfunction is characterized by detrusor overactivity, detrusor sphincter dyssynergia, voiding dysfunction, stress incontinence, or a combination of these and frequently has a negative impact on the patients' health related quality of life. In addition, the treatment of lower urinary tract dysfunction is a challenge because conventional therapies may fail. Adequate treatment and long-term follow-up of lower urinary tract dysfunction is important to achieve/maintain continence and preserve renal function. Thus, we aim to prospectively collect clinical, video-urodynamic and radiological data of patients with neurogenic lower urinary tract dysfunction treated at the University of Zürich in a database.

Official Title
-----------------
Database of Patients With Lower Urinary Tract Dysfunction Treated at the University of Zürich

Conditions
-----------------
Neurogenic Bladder, Diseases of the Lower Urinary Tract: General Conditions

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patient of Balgrist University Hospital patient of University Hospital Zürich urodynamic examination written informed consent Exclusion Criteria: no written informed consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Survival of the patients |  | first visit to death | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
urodynamics, neurogenic lower urinary tract dysfunction, neurological disease/injury
Spermidine Intake and All-cause Mortality

Study Overview
=================
Brief Summary
-----------------
This study seeks to test the potential association between spermidine content in diet and mortality in humans.

Detailed Description
-----------------
This prospective community-based cohort study includes 829 participants aged 45-84 years, 49.9% of which are male. Diet is assessed by repeated dietician-administered validated food-frequency questionnaires (2540 assessments) in 1995, 2000, 2005, and 2010. Nutrient intakes including spermidine are calculated using USDA standard databases. Clinical events (all-cause mortality and cause-specific mortality) are recorded from 1995 to 2015. The primary endpoint of all-cause mortality is related to the exposure of long-term average spermidine intake by Cox proportional hazards models with time-varying covariates. Additional analyses employ the Fine and Gray proportional subdistribution hazards model and flexible Royston-Parmar spline-based models. Comprehensive sensitivity analyses are performed to guard against potential biases associated with nutritional epidemiology.

Official Title
-----------------
Association Between Dietary Spermidine Intake and Mortality in the Population-based Bruneck Study

Conditions
-----------------
Healthy Diet, Mortality

Intervention / Treatment
-----------------
* Other: Spermidine content of natural diet


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Resident of Bruneck aged 40-79 years in 1990, age- and sex-stratified random sample. Exclusion Criteria: None.

Ages Eligible for Study
-----------------
Minimum Age: 45 Years
Maximum Age: 84 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Spermidine content of natural diet|The exposure consists in the long-term average dietary intake of the polyamine spermidine|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| All-cause mortality | Death due to any cause | 1995-2015 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cause-specific mortalities | Death due to cardiovascular disease, cancer, or other causes | 1995-2015 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Polyamine, cardiovascular disease, cancer
Observational Study of a Cohort of Patients With Hereditary Epidermolysis Bullosa

Study Overview
=================
Brief Summary
-----------------
Hereditary Epidermolysis Bullosa (EBH) are rare dermatologic diseases characterized by cutaneous and mucosa fragility. Oral manifestations of few small cohort have been published. The main objective of this multicentric cohort study first in Europe was to report the oral status of these patients that were consulted in the MRDRC of this disease in Nice (France), Toulouse (France) and Louvain (Belgium). Then a correlation between the oral characteristics and the EBH type will be made, in order to facilitate the management of patient care and the prevention program that can be established to improve their oral health.

Official Title
-----------------
Observational Study of a Cohort of Patients With Hereditary Epidermolysis Bullosa That Come for Their Annual/Biannual Check up at This Medical Rare Disease Reference Centers (MRDRC) of This Disease in France and Belgium

Conditions
-----------------
Epidermolysis Bullosa

Intervention / Treatment
-----------------
* Other: clinical exam


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patient with EBH patient consent for examination and use the clinical data for publication purpose Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 7 Months
Maximum Age: 78 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| EBH<br> | Other: clinical exam<br>* clinical oral examination<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Dental structural abnormalities and/or caries | number of defect /dental caries dor each toth | 1 day | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| gingival biotype | clinical observation of gingiva (thin or thick) | 1 day | 
| gingival status | observation and classification of the gingiva (healthy, inflammed or hyperplastic) | 1 day | 
| plaque and gingival index | registration of plaque and gingival index according to the Loë and Silness method | 1 day | 
| oral lesion | number and localisation of the blister/scars/flanges scars on a sketch of a mouth | 1 day |
Real-Time PCR for the Detection of Vaginal Group B Streptococcus Carriage: a Medico-Economic Study

Study Overview
=================
Brief Summary
-----------------
Group B streptococcus infections may be serious for the neonates. The infection can occur during the birth, by contact with the genital area. That is why the detection of this bacteria is systematically realised in pregnant women between 34 and 37 weeks of amenorrhea in order to give prophylactic antibiotic treatment in case or positive carriage. This strategy presents 2 disadvantages : (1) detection of the group B streptococcus at 34 and 37 weeks of amenorrhea in not predictive of a carriage at delivery, (2) many pregnant women escape from systematic screening, leading to a systematic antibiotic treatment, which means useless costs, and useless antibiotic exposure with resistant bacteria selection. Real time polymerase chain reaction (PCR) allows a rapid detection anytime with no specific microbiological qualification. The aim of the study is to assess the economic outcomes of this strategy and the epidemiological values for St Etienne hospital.

Official Title
-----------------
Real-Time PCR for the Detection of Vaginal Group B Streptococcus Carriage at Delivery : a Medico-Economic and Feasibility Study

Conditions
-----------------
Neonatal Infections, Streptococcus Agalactiae

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: women giving birth Exclusion Criteria: planned caesarian minor cervical diameter > 5 cm women giving birth at less than 35 weeks of amenorrhea recent antibiotherapy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Real time PCR monitoring<br>Women giving birth at the St Etienne Teaching Hospital | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| number of women receiving a useless antibiotic prevention |  | 1 day | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| economic outcomes |  | 1 day | 
| epidemiological outcomes for group B streptococcus |  | 1 day | 
| diagnosis efficacy of the real time PCR |  | 1 day | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Screening, real time PCR, Streptococcus agalactiae, Pregnant women
QT Dispersion in Patients With Systemic Lupus Erythematosus (SLE)

Study Overview
=================
Brief Summary
-----------------
QT dispersion can be a useful, simple noninvasive method for the early detection of cardiac involvement in SLE patients with active disease. The investigators therefore recommend cardiovascular evaluation for every SLE patient with an SLEDAI higher than 10.

Detailed Description
-----------------
Objective: Patients with systemic lupus erythematosus (SLE) have increased cardiovascular morbidity and mortality. Although autopsy studies have documented that the heart is affected in most SLE patients, clinical manifestations occur in less than 10%. QT dispersion is a new parameter that can be used to assess homogeneity of cardiac repolarization and autonomic function. We compared the increase in QT dispersion in SLE patients with high disease activity and mild or moderate disease activity. Methods: One hundred twenty-four patients with SLE were enrolled in the study. Complete history and physical exam, ECG, echocardiography, exercise test and SLE disease activity index (SLEDAI) were recorded. Twenty patients were excluded on the basis of our exclusion criteria. The patients were divided to two groups based on SLEDAI: 54 in the high-score group (SLEDAI >10) and 50 in the low-score group (SLEDAI <10).

Official Title
-----------------
QT Dispersion in Patients With Systemic Lupus Erythematosus: the Impact of Disease Activity

Conditions
-----------------
SLE

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: no administration of drugs that would potentially influence QT duration except hydroxychloroquine no history of ischemic heart disease, congestive heart failure, atrial fibrillation, bundle branch block or abnormal serum electrolytes normal resting ECG and a good-quality ECG recording to measure the QT interval. Exclusion Criteria: moderate or severe valve disease atrial fibrillation and other ECG abnormalities systolic left ventricular dysfunction (ejection fraction <50% or left ventricular end diastolic dimension >5.5 mm unreliable identification of the end of the T wave in the ECG and known presence of cardiac disease including hypertension, diabetes or coronary artery disease.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| High SLEDAS<br>High SLE disease activity score | |
| Low SLEDAS<br>SLE patient with low score | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| QT dispersion |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
SLE, Disease activity score, QT dispersion
Prospective and Comparative Analysis of Arthroscopic and Open Surgery for Hallux Rigidus

Study Overview
=================
Brief Summary
-----------------
Comparison between arthroscopic and open surgery for hallux rigidus.

Official Title
-----------------
Prospective and Comparative Analysis of Arthroscopic and Open Surgery for Hallux Rigidus

Conditions
-----------------
Hallux Rigidus

Intervention / Treatment
-----------------
* Procedure: Arthroscopic or open surgery for hallux rigidus


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Hallux rigidus Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Arthroscopic or open surgery for hallux rigidus|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Duration of hospitalisation |  |  | 
| Duration of rehabilitation and sick leave |  |  | 
| Wound healing |  |  |
A Randomised Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of Faster-acting Insulin Aspart in Subjects With Type 1 Diabetes

Study Overview
=================
Brief Summary
-----------------
This trial is conducted in Europe. The aim of the trial is to investigate the pharmacokinetic (the exposure of the trial drug in the body) and pharmacodynamic (the effect of the investigated drug on the body) properties of faster-acting insulin aspart in subjects with Type 1 diabetes.

Official Title
-----------------
A Randomised Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of Faster-acting Insulin Aspart in Subjects With Type 1 Diabetes

Conditions
-----------------
Diabetes, Diabetes Mellitus, Type 1

Intervention / Treatment
-----------------
* Drug: Faster-acting insulin aspart
* Drug: insulin aspart


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male or female 18-64 years (both inclusive) at the time of signing informed consent Type 1 diabetes mellitus (as diagnosed clinically) for at least 12 months Body mass index 18.5-28.0 kg/m^2 (both inclusive) Exclusion Criteria: Subject who has donated any blood or plasma in the past month or more than 500 mL within 3 months prior to screening Smoker (defined as a subject who is smoking at least one cigarette, cigar or pipe daily)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 64 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Faster-acting insulin aspart<br>Each subject will be allocated to two treatments (in random sequence). | Drug: Faster-acting insulin aspart<br>* Subjects will receive a single dose of either Faster-acting insulin aspart or NovoRapid® at a predefined fixed dose level in connection to intake of a standardised meal. Administered subcutaneously (s.c., under the skin)<br>|
| Active Comparator: NovoRapid®<br>Each subject will be allocated to two treatments (in random sequence). | Drug: insulin aspart<br>* Subjects will receive a single dose of either Faster-acting insulin aspart or NovoRapid® at a predefined fixed dose level in connection to intake of a standardised meal. Administered subcutaneously (s.c., under the skin)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mean plasma glucose concentration |  | From 0-6 hours after start of a standardised meal | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Area under the serum insulin aspart concentration-time curve |  | From 0 to 12 hours after trial product administration |
Effects of N-acetyl Cysteine During Primary Percutaneous Coronary Intervention

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to evaluate the effects of N-acetyl cysteine on major cardiac and cerebral events in patients undergoing primary percutaneous coronary intervention who have moderate to high risk for contrast induced nephropathy. In a sub-group of patients coronary flow reserve will be evaluated.

Official Title
-----------------
Effects of N-acetyl Cysteine on Major Cardiac and Cerebral Events in Patients Undergoing Primary Percutaneous Coronary Intervention Who Have Moderate to High Risk For Contrast Induced Nephropathy

Conditions
-----------------
Acute ST Segment Elevation Myocardial Infarction

Intervention / Treatment
-----------------
* Drug: NAC
* Drug: Saline


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with Acute ST Elevation Myocardial Infarction undergoing Primary Percutaneous Coronary intervention Who Have Moderate to High Risk For Contrast Induced Nephropathy (Mehran Score ≥5) Exclusion Criteria: Patients >18 years old with moderate to high risk for contrast induced nephropathy undergoing percutaneous coronary intervention Low risk for contrast induced nephropathy (Mehran Score <5) Use of nephrotoxic agents (NSAIDs, aminoglycosides,recent contrast injection...) Infection Pregnancy, Lactation Renal failure requiring dialysis Hepatic failure Allergy to NAC History of Asthma Chronic nitrate usage Malignancy Use of corticosteroids Leucocytosis,Thrombocytosis,Anemia Blood pressure of >180/100mmHg despite anti-hypertensive therapy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: n-acetyl cysteine<br>30 mg/kg/15 min intravenous bolus preprocedural and 50 mg/kg/8 h intravenous infusion during and after the procedure | Drug: NAC<br> <br> |
| Placebo Comparator: Saline<br>30 mg/kg/15 min intravenous bolus preprocedural and 50 mg/kg/8 h intravenous infusion during and after the procedure | Drug: Saline<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Major cardiac and cerebral events |  | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| NAC side effects (Asthma exacerbation, Pruritus, Dyspnea) |  | during hospitalization at 48 hours |